Cardiogenic Shock

  • S. M. Hollenberg
Conference paper


Cardiogenic shock is one of the most challenging emergencies that intensivists must face. Cardiogenic shock is a syndrome that ensues when the heart is unable to deliver enough blood to maintain adequate tissue perfusion. A rigorous determination requires hemodynamic confirmation, with sustained systemic hypotension (systolic arterial pressure < 90 mmHg or mean arterial pressure (MAP) 30 mmHg or more below basal levels), adequate left ventricular (LV) filling pressures (pulmonary artery wedge pressure > 15 mmHg), and a reduced cardiac output (cardiac index < 2.2 1/min/m2) [1]. In clinical practice, the diagnosis of cardiogenic shock is often made prior to such objective confirmation, by the presence of systemic arterial hypotension with evidence of hypoperfusion in the setting of myocardial dysfunction.


Acute Myocardial Infarction Cardiogenic Shock Fibrinolytic Therapy Primary Angioplasty Coronary Perfusion Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hollenberg SM, Kavinsky CJ, Parrillo JE (1999) Cardiogenic shock. Ann Intern Med 131: 47–59PubMedCrossRefGoogle Scholar
  2. 2.
    Hochman JS, Boland J, Sleeper LA, et al (1995) Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. Circulation 91: 873–881PubMedCrossRefGoogle Scholar
  3. 3.
    Goldberg RJ, Yarzebske J, Lessard D, Gore JM (1999) A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 33: 1533–1539PubMedCrossRefGoogle Scholar
  4. 4.
    Holmes DR Jr, Bates ER, Kleiman NS, et al (1995) Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 26: 668–674PubMedCrossRefGoogle Scholar
  5. 5.
    Webb JG, Sleeper LA, Buller CE, et al (2000) Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 36 (3 suppl A): 1084–1090PubMedCrossRefGoogle Scholar
  6. 6.
    Scheidt S, Ascheim R, Killip T (1970) Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol 26: 556–564PubMedCrossRefGoogle Scholar
  7. 7.
    Killip T, Kimball JT (1967) Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 20: 457–464PubMedCrossRefGoogle Scholar
  8. 8.
    Hands ME, Rutherford JD, Muller JE, et al (1989) The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 14: 40–46PubMedCrossRefGoogle Scholar
  9. 9.
    Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S (1993) Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med 94: 265–273PubMedCrossRefGoogle Scholar
  10. 10.
    Hochman JS, Sleeper LA, Webb JG, et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 341: 625–634PubMedCrossRefGoogle Scholar
  11. 11.
    Grines CL, Topol EJ, Calif RM, et al (1989) Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. Circulation 80: 245–253PubMedCrossRefGoogle Scholar
  12. 12.
    Alonso DR, Scheidt S, Post M, Killip T (1973) Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 48: 588–596PubMedCrossRefGoogle Scholar
  13. 13.
    Harizi RC, Bianco JA, Alpert JS (1988) Diastolic function of the heart in clinical cardiology. Arch Intern Med 148: 99–109PubMedCrossRefGoogle Scholar
  14. 14.
    Bolli R (1998) Basic and clinical aspects of myocardial stunning. Prog Cardiovasc Dis 40: 477–516PubMedCrossRefGoogle Scholar
  15. 15.
    Wijns W, Vatner SF, Camici PG (1998) Hibernating myocardium. N Engl J Med 339: 173–181PubMedCrossRefGoogle Scholar
  16. 16.
    Hansen RM, Viquerat CE, Matthay MA, et al (1986) Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary aftery bypass graft surgery. Anesthesiology 64: 764–770PubMedCrossRefGoogle Scholar
  17. 17.
    Pang D, Keenan SP, Cook DJ, Sibbald WJ (1998) The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest 114: 1185–1192PubMedCrossRefGoogle Scholar
  18. 18.
    Hollenberg SM, Hoyt JW (1997) Pulmonary artery catheters in cardiovascular disease. New Horiz 5: 207–213PubMedGoogle Scholar
  19. 19.
    Willerson JT, Curry GC, Watson JT, et al (1975) Intraaortic balloon counterpulsation in patients in cardiogenic shock, medically refractory left ventricular failure and/or recurrent ventricular tachycardia. Am J Med 58: 183–191PubMedCrossRefGoogle Scholar
  20. 20.
    Bates ER, Stomel RJ, Hochman JS, Ohman EM (1998) The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. Int J Cardiol 65 (suppl 1): S37 - S42PubMedCrossRefGoogle Scholar
  21. 21.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311–322Google Scholar
  22. 22.
    GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682CrossRefGoogle Scholar
  23. 23.
    Ryan TJ, Antman EM, Brooks NH, et al (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Cornmittee on Management of Acute Myocardial Infarction ). J Am Coll Cardiol 34: 890–911PubMedCrossRefGoogle Scholar
  24. 24.
    AIMS Trial Study Group (1988) Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1: 545–549Google Scholar
  25. 25.
    Col NF, Gurwitz JH, Alpert JS, Goldberg RJ (1994) Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. Am J Cardiol 73: 149–157PubMedCrossRefGoogle Scholar
  26. 26.
    Gruppo Italiano per lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 2: 397–402Google Scholar
  27. 27.
    Sanborn TA, Sleeper LA, Bates ER, et al (2000) Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 36 (3 suppl A): 1123–1129PubMedCrossRefGoogle Scholar
  28. 28.
    Becker RC (1993) Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J 125: 919–929PubMedCrossRefGoogle Scholar
  29. 29.
    Garber PJ, Mathieson AL, Ducas J, Patton JN, Geddes JS, Prewitt RM (1995) Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration. Can J Cardiol 11: 30–36PubMedGoogle Scholar
  30. 30.
    O’Keefe JH Jr, Bailey WL, Rutherford BD, Hartzler GO (1993) Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients. Results in an unselected population and high-risk subgroups. Am J Cardiol 72: 107G - 115GPubMedCrossRefGoogle Scholar
  31. 31.
    Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Calif RM, Topol EJ (1997) Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 96: 122–127PubMedCrossRefGoogle Scholar
  32. 32.
    Berger PB, Tuttle RH, Holmes DR Jr, et al (1999) One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: Results from the GUSTO-I trial. Circulation 99: 873–878PubMedCrossRefGoogle Scholar
  33. 33.
    Rogers WJ, Canto JG, Lambrew CT, et al (2000) Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 36: 2056–2063PubMedCrossRefGoogle Scholar
  34. 34.
    Hochman JS, Sleeper LA, White HD, et al (2001) One-year survival following early revascularization for cardiogenic shock. JAMA 285: 190–192PubMedCrossRefGoogle Scholar
  35. 35.
    Urban P, Stauffer JC, Bleed D, et al (1999) A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The ( Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 20: 1030–1038PubMedCrossRefGoogle Scholar
  36. 36.
    Urban P, Stauffer J-C (2002) Randomized trials of revascularization therapy for cardiogenic shock. In: Hollenberg SM, Bates ER (eds) Cardiogenic Shock. Futura Publishing Company, Armonk, pp 135–144Google Scholar
  37. 37.
    Stone GW, Brodie BR, Griffin JJ, et al (1998) Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol 31: 23–30PubMedCrossRefGoogle Scholar
  38. 38.
    Schomig A, Neumann FJ, Walter H, et al (1997) Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 29: 28–34PubMedCrossRefGoogle Scholar
  39. 39.
    Stone GW, Brodie BR, Griffin JJ, et al (1999) Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction ( PAMI) stent pilot trial. Circulation 99: 1548–1554PubMedCrossRefGoogle Scholar
  40. 40.
    Antoniucci D, Valenti R, Santoro GM, et al (1998) Systematic direct angioplasty and stentsupported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol 31: 294–300PubMedCrossRefGoogle Scholar
  41. 41.
    Webb JG, Carere RG, Hilton JD, et al (1997) Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol 79: 81–84PubMedCrossRefGoogle Scholar
  42. 42.
    Montalescot G, Barragan P, Wittenberg O, et al (2001) Platelet glycoprotein IIb/IJIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895–1903PubMedCrossRefGoogle Scholar
  43. 43.
    Diaz R, Paolasso EA, Piegas LS, et al (1998) Metabolic modulation of acute myocardial infarction. Circulation 98: 2227–2234PubMedCrossRefGoogle Scholar
  44. 44.
    Barron HV, Every NR, Parsons LS, et al (2001) Use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 141: 933–939PubMedCrossRefGoogle Scholar
  45. 45.
    Kovack PJ, Rasak MA, Bates ER, Ohman EM, Stomel RJ (1997) Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol 29: 1454–1458PubMedCrossRefGoogle Scholar
  46. 46.
    Stomel RJ, Rasak M, Bates ER (1994) Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital. Chest 105: 997–1002PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • S. M. Hollenberg

There are no affiliations available

Personalised recommendations